Market Domination hosts Josh Lipton and Julie Hyman go over some of the day's top trending tickers. Novavax (NVAX) stock is soaring after the company's COVID-19 vaccine was approved by the US Food and Drug Administration (FDA). Shake Shack (SHAK) was downgraded by TD Cowen to Hold from Buy, citing limited multiple expansion. Solar stocks, including First Solar (FSLR), Sunrun (RUN), and Enphase (ENPH), are sinking after Republican lawmakers confirmed that clean-energy tax credits will be ending earlier than planned. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Video Transcript 00:00 Julie Hyman Now time for some of today's trending tickers. We're checking on shares of Novavax, Shake Shack and some solar stocks. First up Novavax surging today after its protein-based COVID-19 vaccine received its long-awaited approval from the US Food and Drug Administration. And even though that approval came with some conditions, the fact that it happened at all was enough to send the shares soaring by about 15%, Josh. 00:23 Josh Lipton Yeah, from what I read, Julie, they expected to secure approvals, I guess, for vaccine on April 1. And then they faced these delays, and the FDA, I guess, asked for more data, so some relief from investors perhaps. Also Moderna, by the way, which of course, also makes the COVID shots. That's enjoying a nice day in the green, too. Up about 6%. 00:49 Julie Hyman Right. 00:54 Julie Hyman Yeah, so, so the conditions on this is that the shot is okayed for adults 65 and older, and those who are 12 to 64 who have at least one underlying condition. So higher risk patients, basically, older adults and higher risk patients. Not cleared for children as far as I understand it. And really what this removes is a concern that Robert F. Kennedy, of course, the HHS Secretary, was going to block this entirely. So this is sort of, at least the market is reading it as a bigger indication of perhaps his attitude towards these types of vaccines. But we'll see if it goes beyond Novavax or not. 01:38 Josh Lipton Right. Something broader. 01:44 Josh Lipton We will. All right, switching gears. Shares of Shake Shack, they're taking a hit today after being downgraded to a hold from TD Cowen. And so those analysts, they do cut the rating, they go to the sidelines to the hold. They talk about high valuation, saying the challenged restaurant spending backdrop limits further multiple expansion, particularly in the crowded burger category. They highlight also the big run since that 52-week low set in early April, Julie. 02:18 Julie Hyman Yeah, they're also talking about marketing spending, and that the company's not spending as much on marketing, which they say this might be, there's a stronger year-over-year benefit to sales from advertising because they're not going to be advertising as much. Um, they, you know, so that's one of the other things here. They also talked about digital offers are stepping up in the first half of this year, which may be an indication about demand here that maybe they, that frequent customers need them, need a little more sugar, need a little more of an enticement to get in the door. 03:07 Josh Lipton So yes, so they did take it down. Their target stays at 105, by the way. 03:18 Julie Hyman Um, and then finally let's look at solar stocks here, which are moving as a group today for solar, Sunrun, Enphase Energy. They're all sinking after conservative Republican lawmakers said they had secured a commitment from leadership to end key clean energy tax credits earlier than planned. You know, this all part of the big bill, tax bill, trying to make its way through Congress here. Um, and basically the energy credits, there was a tax incentive for clean energy production, among other things, would initially, they were supposed to start phasing out in 2029 and then end in 2032. This reporting says it could happen earlier than that, but it's not clear how much earlier. But obviously there's a lot of sensitivity and concern around these credits more broadly, and what this administration and Congress are going to do to various pieces of the IRA going forward. 04:17 Josh Lipton Yeah. Per Bloomberg, Representative Ralph Norman of South Carolina, who's helping negotiate the package, it doesn't sound like we didn't provide a new time frame exactly. So we're not sure. And ultimately, of course, you still have to decide, what do Republicans really do with this in the House, including those described as more moderates, and then of course, then on to the Senate. Related Videos 10:52 Fed's Bostic on Rate Policy, Tariffs, Framework Review Bloomberg • 34 minutes ago 05:57 Tech Stocks Volatility After US Credit Downgrade Bloomberg • 1 hour ago 04:06 Your 401(k) and private market investments: What to know Yahoo Finance Video • 1 hour ago 01:00 Gold rebounds, Palantir shares slide, UBS boosts airline stocks Yahoo Finance Video • 1 hour ago View Comments
Novavax, Shake Shack, solar stocks: Trending Tickers
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...